

2009

The Pic Protease of Enteroaggregative *Escherichia coli* Promotes Intestinal Colonization and Growth in the Presence of Mucin

Susan M. Harrington

Jalaluddin Sheikh

See next page for additional authors

Follow this and additional works at: https://digitalcommons.uri.edu/cmb_facpubs

Terms of Use

All rights reserved under copyright.

Citation/Publisher Attribution

Harrington, S. M., Sheikh, J., Henderson, I. R., Ruiz-Perez, F., Cohen, P. S., & Nataro, J. P. (2009). The Pic Protease of Enteroaggregative *Escherichia coli* Promotes Intestinal Colonization and Growth in the Presence of Mucin. *Infection and Immunity*, 77(6), 2465-2473. doi: 10.1128/IAI.01494-08

Available at: <http://dx.doi.org/10.1128/IAI.01494-08>

This Article is brought to you for free and open access by the Cell and Molecular Biology at DigitalCommons@URI. It has been accepted for inclusion in Cell and Molecular Biology Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.

Authors

Susan M. Harrington, Jalaluddin Sheikh, Ian R. Henderson, Fernando Ruiz-Perez, Paul S. Cohen, and James P. Nataro

The Pic Protease of Enteroaggregative *Escherichia coli* Promotes Intestinal Colonization and Growth in the Presence of Mucin[∇]

Susan M. Harrington,¹ Jalaluddin Sheikh,^{1,2} Ian R. Henderson,³ Fernando Ruiz-Perez,² Paul S. Cohen,⁴ and James P. Nataro^{1,2*}

Center for Vaccine Development, University of Maryland School of Medicine, and Departments of Microbiology and Immunology¹ and Pediatrics,² University of Maryland School of Medicine, Baltimore, Maryland 21201; School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom³; and Department of Cell and Molecular Biology, University of Rhode Island, Kingston, Rhode Island 02881⁴

Received 8 December 2008/Returned for modification 8 January 2009/Accepted 26 March 2009

Enteroaggregative *Escherichia coli* (EAEC) is increasingly being recognized as a cause of diarrheal disease in diverse populations. No small animal model is currently available to study this pathogen. We report here that conventional mice orally inoculated with prototype EAEC strain 042 generally became colonized, though the abundance of organisms cultured from their stool varied substantially among individual animals. In contrast, mice whose water contained 5 g/liter streptomycin consistently became colonized at high levels (ca. 10⁸ CFU/g of stool). Neither conventional nor streptomycin-treated mice developed clinical signs or histopathologic abnormalities. Using specific mutants in competition with the wild-type strain, we evaluated the contribution of several putative EAEC virulence factors to colonization of streptomycin-treated mice. Our data suggest that the dispersin surface protein and Pic, a serine protease autotransporter secreted by EAEC and *Shigella flexneri*, promote colonization of the mouse. In contrast, we found no role for the aggregative adherence fimbriae, the transcriptional activator AggR, or the surface factor termed Air (enteroaggregative immunoglobulin repeat protein). To study Pic further, we constructed a single nucleotide mutation in strain 042 which altered only the Pic catalytic serine (strain 042PicS258A). Fractionation of the tissue at 24 h and 3 days demonstrated an approximate 3-log₁₀ difference between 042 and 042PicS258A in the lumen and mucus layer and adherent to tissue. Strains 042 and 042PicS258A adhered similarly to mouse tissue ex vivo. While no growth differences were observed in a continuous-flow anaerobic intestinal simulator system, the wild-type strain exhibited a growth advantage over 042PicS258A in a culture of cecal mucus and in cecal contents in vitro; this difference was manifest only after 6 h of growth. Moreover, enhanced growth of the wild type was observed in comparison with that of the mutant in minimal medium containing mucin but not in the absence of mucin. The data suggest a novel metabolic role for the Pic mucinase in EAEC colonization.

Enteroaggregative *Escherichia coli* (EAEC) is an emerging agent of diarrheal illness in multiple epidemiologic settings (19). The pathogen has been associated with persistent diarrhea in children (4, 5), acute endemic diarrhea (38), persistent diarrhea in AIDS patients (13), food-borne outbreaks (20), and traveler's diarrhea (1). Pathogenesis is believed to occur in the ileum and colon, where the bacteria adhere in a thick, aggregating biofilm, mediated by aggregative adherence fimbriae (AAFs) (7, 21, 28). Following adherence, EAEC causes tissue damage and fluid secretion by elaborating one or more enterotoxins, including the Pet cytotoxin (31), EAST1 (39) and/or ShET1 (11, 12).

Adherence to human intestinal mucosa ex vivo requires the expression of AAFs (7), although additional colonization factors are likely to contribute. We have also described dispersin, a 10-kDa hydrophilic protein which attaches noncovalently to the bacterial cell surface (40). Both dispersin and AAF/II, the AAF allele expressed by strain 042, are under the control of the transcriptional activator AggR (7, 30, 40). In the absence of dispersin, AAF pili collapse onto the surface of the cells, and

the bacteria display a hyperaggregative phenotype (40). We have also shown, however, that dispersin mutants are impaired in their abilities to penetrate an artificial mucus layer (40), and they may therefore be paradoxically more adherent but less adept at colonization. In addition, EAEC genome characterization has identified an adhesin called Air (enteroaggregative immunoglobulin repeat protein), which features a large number of immunoglobulin-like repeats and which may promote bacterial aggregation and colonization (41).

In addition to toxins and adhesins, EAEC secretes Pic, a protein with hemagglutinin and mucinolytic activity in vitro (17). Some epidemiologic studies suggest a role for *pic* or its linked genes in EAEC disease (35). Notably, *pic* alleles are also present in *Shigella flexneri* 2a (36) and in uropathogenic *E. coli* (UPEC) strains (16). Guyer et al. found *pic* to be more common among pyelonephritis isolates than fecal strains, suggesting a role in urinary tract infections (15, 34). In the CBA mouse model of ascending urinary tract infections, wild-type UPEC tended to colonize better than a *pic* mutant (16); however, this difference did not reach statistical significance, and further studies have not been reported.

Pic is a 116-kDa secreted autotransporter protein of the SPATE (serine protease autotransporter of enterobacteriaceae) family (18). Sequence alignments and functional comparisons (9) have shown that Pic and its alleles are most similar

* Corresponding author. Mailing address: University of Maryland, 685 W. Baltimore St., Baltimore, MD 21201. Phone: (410) 706-5328. Fax: (410) 706-6205. E-mail: jnataro@medicine.umaryland.edu.

[∇] Published ahead of print on 6 April 2009.

TABLE 1. Characteristics and source of host strains and plasmids used in this study

Strain or plasmid	Relevant characteristic(s) ^a	Source or reference
<i>E. coli</i> strains		
042	Prototype EAEC strain (044:H18) <i>lac</i> ⁺ , Sm Tc Cm	27
042PicS258A	042 Ser258 to Ala	This study
042PicS258A (Nal ^r)	Nal derivative of 042PicS258A	This study
042 <i>pic::aph3</i>	042 Km insertion in <i>pic</i>	This study
042 <i>aap</i>	042 harboring pJP5603 inserted into <i>aap</i> , Km	39
042 <i>aafA</i> 3.4.14	042 harboring Tn <i>phoA</i> inserted into the <i>aafA</i> gene, Km	7
042 <i>aggR</i>	042 harboring pJP5603 inserted into <i>aggR</i> , Km	28
042 <i>air</i>	042 harboring pJP5603 inserted into <i>air</i> , Km	40
DH5α	F' ϕ 80 <i>dlacZ</i> ΔM15 Δ(<i>lacZYA-argF</i>)U169 <i>endA1 recA1 hsdR17 supE44 thi-1 gyrA96 relA1 phoA</i>	37
SY327λ <i>pir</i>	Δ(<i>lac pro</i>) <i>argE</i> (Am) <i>rif nalA recA56</i>	22
SM10λ <i>pir</i>	<i>thr thi leu tonA lacY supE recA::RP4-2-Tc::Mu</i> (Km)	42
HS	Commensal <i>E. coli</i> , Sm	18
Plasmids		
pPic	pACYC184 derivative containing an EcoRI-ScaI genomic fragment containing <i>pic</i> cloned from EAEC strain 042, Tc	14
pPicS258A	pPic, Ser 258 to Ala	This study
pPic::aph3	pPic (Km insertion at Ala 254)	This study
pCVD442	6.2-kb suicide vector, R6K origin, Ap	8
pSMH1	2-kb pPicS258A PCR product cloned into pCVD442	This study
pSMH2	3-kb p <i>Picaph3</i> PCR product cloned into pCVD442	This study
pK18	Contains aminoglycoside 3'-O-phosphotransferase (<i>aph3</i>)	34

^a Ap, ampicillin resistance; Tc, tetracycline resistance; Cm, chloramphenicol resistance; Km, kanamycin resistance; Sm, streptomycin resistance; Nal, nalidixic acid resistance; *lac*, lactose fermentation.

to the SPATE proteins Tsh from avian pathogenic *E. coli* (43), an identical protein termed Hbp from a human pathogenic isolate (33), and SepA from *Shigella flexneri* (3). Both Tsh (22) and another SPATE from enterohemorrhagic *E. coli*, termed EpeA (24), have been reported to be mucinolytic. These reports demonstrate the potential for this group of the SPATE proteins to contribute to pathogenesis, perhaps via mucus layer interaction and mucosal colonization.

The streptomycin-treated mouse is a well-established model for studying *E. coli* colonization and interactions with the mucus layer; *E. coli* mutants with a reduced ability to penetrate mucus (25, 27) and grow in mucus (45) have been shown to exhibit colonization defects in this model. Here, we report that EAEC isolates are able to efficiently colonize the mouse intestine only when the animal is pretreated with streptomycin. In addition, our studies suggest roles for dispersin and Pic in intestinal colonization.

MATERIALS AND METHODS

Strains and plasmids. Isolated from a child with diarrhea in Lima, Peru, the prototype EAEC 042 strain caused diarrhea in adult volunteers (29) and was used for the generation of all isogenic strains. Strain 042 is naturally streptomycin resistant. A streptomycin-resistant derivative of the commensal *E. coli* strain HS (23) was generated by selection on Luria-Bertani (L) agar plates with 100 μg/ml streptomycin. Other strains and plasmids used for genetic manipulations are listed in Table 1. Strains were grown in L broth or maintained on L agar with ampicillin (100 μg/ml), kanamycin (50 μg/ml), nalidixic acid (50 μg/ml), and streptomycin (100 μg/ml) as required. All antibiotics were purchased from Sigma Chemical Co. (St. Louis, MO).

Construction of isogenic mutants in strain 042. Mutations in the genes *aggR*, *aap*, *air*, and *aafA* were constructed by single-crossover integration of suicide plasmid pJP5603, and all were described previously (7, 30, 40, 41) (Table 1).

The *pic* and *setLAB* loci are overlapping genes encoded on opposite strands; a *pic* mutant was constructed in which *pic* is inactivated via exchange of the catalytic serine with alanine, without disruption of *setBA*. The catalytic serine in Pic was first changed to alanine by site-directed mutagenesis in pPic, a previously

described pACYC184 derivative containing a genomic fragment encoding full-length *pic*, cloned from strain 042 (17) to yield strain pPicS258A. Site-directed mutagenesis employed QuikChange according to the manufacturer's protocols (Stratagene, La Jolla, CA) and using 25 ng of plasmid template DNA, 125 ng of primers PicMut-F and PicMut-R (Table 2), 0.5 mM deoxynucleoside triphosphate mix, 1× buffer, and 2.5 U *Pfu* Turbo DNA polymerase (Stratagene). Cycling conditions were 95°C for 30 s, followed by 20 cycles of 95°C for 30 s, 55°C for 1 min, and 68°C for 20 min. Confirmation of mutations by nucleotide sequencing was performed at the University of Maryland Biopolymer Core Facility. To introduce this mutation into strain 042, an approximately 2-kb region encoding the C-terminal half of the *pic* gene product in strain pPicS258A was amplified with primers designated PicKmSphI-F and PicKmXbaI-R (Table 2) containing restriction sites for SphI and XbaI. The PCR product was subcloned into the SphI and XbaI sites in the suicide vector pCVD442 to generate pSMH1 and was transformed into chemically competent SY327λ*pir* (8). Purified pSMH1 was subsequently transformed into SM10λ*pir* (8) for mating with EAEC strain 042. Allelic exchange was performed as described previously (8). The S258A point mutation was verified by nucleic acid sequence analysis. To facilitate the recovery of strains in coinfection experiments, a nalidixic acid-resistant derivative of strain 042PicS258A was generated by being plating on L agar containing 50 μg/ml nalidixic acid.

The *pic* gene was also insertionally inactivated in strain 042 using a similar approach. To construct a site into which the kanamycin resistance gene would be cloned, a NotI restriction site was inserted in pPic by inverse PCR analysis. The reaction was performed as for site-directed mutagenesis, using primers PicNotI-F and PicNotI-R (Table 2). Cycling conditions were 95°C for 30 s, followed by 18 cycles of 95°C for 30 s, 60°C for 1 min, and 68°C for 25 min. The PCR product was gel purified, ligated, and transformed into DH5α. The Tn5 aminoglycoside 3'-O-phosphotransferase gene (*aph3*) encoding resistance to kanamycin was amplified from pK18 with primers KanNotI-F and KanNotI-R (Table 2). The 1,029-bp product of this reaction was gel purified and cloned into the NotI site in pPic to generate p*Picaph3*. A 3.1-kb region of p*Picaph3* was then amplified such that the kanamycin resistance gene would be flanked by 1 kb of the *pic* sequence using the primers PicKmXbaI-F and PicKmXbaI-R (Table 2) containing restriction sites for XbaI. Allelic exchange was performed as described above.

Bacterial growth curves. Growth of strain 042 and its mutants in various growth media was performed by subculturing overnight broth cultures into the appropriate medium in triplicate and reading the optical density at 600 nm (OD₆₀₀) at various time points. Data represent the means of the three points. Growth in minimal medium was performed in M9 medium with 1% glucose;

TABLE 2. Primers for construction of *pic* mutants

Primer designation	Sequence ^a
PicMut-F.....	5'-GGAGCCCCTGGGGATGCTGGTTCTCCTTTGTTTCG
PicMut-R.....	5'-GCAAACAAAGGAGAACCAGCATCCCCAGGGGCTCC
PicNotI-F.....	5'-AAGGAAAAAAGCGGCCGCGCTGGGGATAGTGGTTCTCCTTTG
PicNotI-R.....	5'-AAGGAAAAAAGCGGCCGCGCTCCATAGTCAGGTAAGGCGCC
KanNotI-F.....	5'-AAGGAAAAAAGCGGCCGCGCTTGCAGTGGGCTTACATG
KanNotI-R.....	5'-AAGGAAAAAAGCGGCCGCGGTCATTTTCAACCCAGAG
PicKmSphI-F.....	5'-ACATCCATGCCTGGCATTAAAGGCTACATACGGC
PicKmXbaI-R.....	5'-CTAGTCTAGACTGAGCCGATCATTTCAGGCTG
PicKmXbaI-F.....	5'-CTAGTCTAGACTGGCATTAAAGGCTACATACGGC
PicKmXbaI-R.....	5'-CTAGTCTAGACTGAGCCGATCATTTCAGGCTG

^a Underlined nucleotides indicate the Ser-to-Ala mutation site.

0.05% glucose was employed during experiments in which mucin was added. The mucin used was bovine submaxillary mucin preparation obtained from Sigma Chemical Co., St. Louis, MO.

Mouse colonization. The streptomycin-treated mouse model was adapted from previous reports (26, 32). Eleven- to 12-week-old female BALB/c mice (Charles River Laboratories, Wilmington, MA) were provided with drinking water ad libitum containing 5 g/liter streptomycin from 24 to 48 h prior to inoculation and for the duration of the experiment. Stool samples were documented to be free of streptomycin-resistant *E. coli* at the time of inoculation. Inoculation strains were grown overnight in L broth, diluted 1:500, and incubated to late exponential phase (approximately 6 h). Bacteria were pelleted by centrifugation, washed once with sterile phosphate-buffered saline (PBS; pH 7.4), and resuspended in PBS to a final concentration of 5×10^3 CFU/ml. For coinfections, a 1:1 mixed suspension of strain 042 and the mutant was prepared at a final total concentration of 1×10^4 CFU/ml. Prior to infection with bacterial strains, mice were given 0.2 ml half-saturated sodium bicarbonate solution orogastrically to neutralize gastric acid. Approximately 15 min later, 0.2 ml of the inoculum was administered orogastrically. Bacterial inocula were quantified by plate counts. Fresh fecal pellets were collected at the indicated time points for up to 15 days postinfection. Feces were weighed, diluted, and homogenized in sterile PBS; serial dilutions were plated on MacConkey agar (Sigma) with antibiotics. Antibiotic concentrations used in these media were 100 µg/ml streptomycin for strain 042, 100 µg/ml streptomycin and 10 µg/ml nalidixic acid for strain 042PicS258A, or 100 µg/ml streptomycin and 25 µg/ml kanamycin for all other mutants. The limit of detection was approximately 10^3 CFU/g feces. For cultures in which colony counts were less than the lower limit of detection, statistical analysis was performed with values set at the limit of detection.

For enumeration of bacteria in intestinal compartments, a 2- to 3-cm section of the ileum that was approximately 1 cm away from the ileo-cecal valve, an ~2-cm length of the colon, and the entire cecum were excised. Luminal contents were expelled and weighed, and serial dilutions were made in PBS for plating to MacConkey agar; bacterial counts were expressed as CFU/gram of intestinal content. Intestinal segments were opened and rinsed thoroughly in PBS to remove fecal material, homogenized in 1 ml PBS with a Handi-Shear tissue homogenizer (VirTis, Gardiner, NY), and diluted in PBS for plating on MacConkey agar. For quantitation of bacteria colonizing the mucus layer, tissue was washed with PBS and then the mucus layer was removed by being scraped with a rubber spatula. Mucus was diluted in 200 µl PBS, and serial dilutions were plated on MacConkey agar. After being scraped, the tissue was homogenized and bacterial counts were determined as described above.

Growth in cecal luminal contents and in cecal mucus. The experiments defining growth in mucus and cecal contents in vitro were performed as previously described (46). Twenty CD-1 5-week-old male mice (Charles River Laboratories, Wilmington, MA) were given pine shaving bedding, sterile water, and mouse and rat diet (Harlan Teklad, Madison, WI) and acclimatized to the facilities for approximately 1 week. Mice were given 5 g/liter streptomycin sulfate in their drinking water, provided ad libitum, for 1 day. Ten mice were asphyxiated using CO₂, and their ceca were excised; contents were collected into a 15-ml tube kept on ice. The cecal tissue was then rinsed in a petri dish filled with ice-cold HEPES-Hanks' buffer (HHB; 8 g NaCl, 0.4 g KCl, 0.14 g CaCl₂ · 2H₂O, 0.20 g MgSO₄ · 7H₂O, 0.05 g Na₂HPO₄, 0.35 g KH₂PO₄, 2.6 g HEPES per liter). Ceca were blotted dry on paper towels, and mucus was scraped off of the tissue into a petri dish using a soft rubber policeman; mucus from these 10 mice was pooled for later use.

Overnight L broth bacterial cultures were grown at 37°C in a shaking water bath. One milliliter of cells from *E. coli* strains 042 and 042PicS258A was pelleted

at 10,000 rpm for 1.5 min. The pellet was rinsed with cold HHB and resuspended in 1 ml HHB. The washed bacteria were mixed together and inoculated into the pooled mucus sample or the pooled cecal contents to produce a final inoculum concentration of 10^4 CFU/ml. Following inoculation, the mucus or cecal cultures were incubated overnight at 37°C in a shaking water bath. At each time point, 50 µl was removed, diluted 10-fold in HHB, and plated on MacConkey agar plates containing 100 µg/ml streptomycin sulfate or 100 µg/ml streptomycin sulfate and 50 µg/ml nalidixic acid. Plates were incubated at 37°C overnight. From the cultures in mucus, samples were taken at time zero and at 2, 4, 6, 8, and 24 h. From the cultures in cecal contents, samples were taken at time zero and at 24 h.

For longer incubation experiments, *E. coli* 042 and 042PicS258A were grown to late logarithmic phase and added to mucus at a final concentration of 1×10^5 CFU/ml. Sampling from cultures was performed at 0, 6, 12, and 24 h and daily, thereafter, for 6 days. Fresh streptomycin was added to the culture each day to a final concentration of 50 µg/ml.

Adherence to mouse colonic tissue. This protocol was adapted from the method described by El Asmar et al. (10). Eleven- to 12-week-old female BALB/c mice were given 5 g/liter streptomycin in their drinking water for 48 h prior to collection of colonic tissue. Mice were anesthetized with isoflurane (Abbott, Chicago, IL) and sacrificed by cervical dislocation. The entire colon was excised and rinsed thoroughly in sterile PBS, pH 7.4. Tissue segments ~0.5 cm in length were cut and placed mucosal side up onto polycarbonate filters cut from a Snapwell tissue culture chamber (Corning Costar). The tissue and filter were sandwiched between two plastic rings with a 3-mm-diameter central hole and placed back into the Snapwell chamber. Tissues were equilibrated for 30 min at 37°C in an atmosphere of 5% CO₂ in prewarmed Dulbecco's modified Eagle medium containing 4.5 g/liter glucose, L-glutamine, 110 mg/liter sodium pyruvate, and pyridoxine hydrochloride. Five milliliters of Dulbecco's modified Eagle medium was added to the serosal side and 200 µl to the mucosal side of the tissue in the chamber.

Bacterial strains were grown to late logarithmic phase, washed, and standardized as described for previous studies. Following the tissue equilibration period, 5 µl of 1×10^8 CFU/ml of each strain was added to the mucosal side of each of three wells. Cocultures were also performed in triplicate using 5 µl of a mixed culture of strains 042 and 042PicS258A or 042 and 042 *pic::aph3* with each strain at 1×10^8 CFU/ml. Snapwell chambers were incubated at 37°C for 3 h. After the incubation period, chambers were washed five times with PBS to remove non-adherent bacteria. Tissue was removed and homogenized in 200 µl PBS in Eppendorf tubes with plastic pestles using a pellet pestle motor (Kontes). Homogenates were diluted and plated on MacConkey media as described above. Adherent bacteria were quantified as CFU/tissue segment because the area of tissue available for bacterial adherence was identical for each well.

Growth competition assay in a continuous-flow fermentor. EAEC strains 042 and 042PicS258A were grown simultaneously in a continuous-flow anaerobic culture either with or without introduction of a human fecal sample as previously described (37). The fecal sample comprised 60 g of fresh stool from a healthy human subject. After addition of the fecal sample, the system was stabilized for at least 24 h at pH 6.5. Following the stabilization period, the system was inoculated with 50 ml of a mixed culture of strains 042 and 042PicS258A to a final concentration of 10^7 CFU/ml each. The continuous-flow culture was sampled at 6, 12, and 24 h and once a day for 5 days postinoculation. Samples were diluted and plated on MacConkey media with appropriate antibiotics. Culture plates were incubated, and strains were quantified as described for previous experiments.

Statistical analysis. Analyses were performed on log-transformed data for all colony counts, employing software available at the Universiteit van Amsterdam

website (www.fon.hum.uva.nl/). The paired *t* test was used to compare means of log-transformed data from different sites of the mouse intestine. For the adherence assay involving multiple comparisons, statistical analysis was performed with a one-way analysis of variance, followed by Bonferroni error correction, using the Analyze-it add-in for Microsoft Excel database software. For in vitro growth experiments, means of log₁₀ CFU per milliliter were compared by using the paired Student's *t* test (two-tailed) using Excel database software.

RESULTS

Colonization of BALB/c mice with EAEC. We infected 11- to 12-week-old BALB/c mice with high doses of EAEC after neutralization of gastric acidity. We found that EAEC strain 042 colonized inconsistently and was often eliminated within 3 days of inoculation. Excretion levels ranged from 0 to 10⁵ CFU/g of feces, typically higher during the first day after inoculation. All mice remained clinically well with normal intestinal histopathology.

The streptomycin-treated mouse model has been used to study intestinal colonization with *E. coli* and *Salmonella* spp. (32, 45), and the model has recently been shown to be useful for inducing colitis with *Salmonella* strains (44). The prototype strain 042 is naturally resistant to streptomycin. Mice were given water containing 5 g/liter streptomycin ad libitum for 24 to 48 h prior to inoculation and for the duration of the experiment. Strain 042 colonized streptomycin-treated mice consistently, at levels of approximately 10⁸ to 10⁹ CFU/g of stool. Mice remained colonized as long as streptomycin was provided in the water, though they commonly cleared colonization when streptomycin was removed. All mice remained well. Histopathologic examination of infected mice was normal.

Effects of EAEC adherence factors on mouse gastrointestinal (GI) colonization. Since streptomycin treatment resulted in high levels of colonization, we sought to determine whether the model could be used to assess the contribution of putative EAEC colonization factors. We tested mutants in the AAF/II-encoding genes, the global regulator AggR, the dispersin coat protein, and a recently discovered agglutinin called Air for the ability to colonize streptomycin-treated mice.

An inoculum of 1 × 10³ CFU of each strain was introduced individually to groups of four to eight mice, and fecal colonization was quantified for up to 12 days. All mutants were able to colonize streptomycin-treated mice when fed individually at levels not significantly different from that of strain 042 (data not shown).

Competition between the mutants and the wild-type strain was then employed as a more sensitive readout of colonization efficiency. Accordingly, mice were infected simultaneously with 1 × 10³ CFU each of strain 042 and one of the isogenic mutants. Isogenic strains with mutations in *aafA*, *air*, and surprisingly *aggR* cocolonized at levels similar to that of the wild-type parent. However, strain 042 *aap*, which contains a mutation in the gene encoding the dispersin protein coat and which displays a hyperaggregative phenotype in vitro, was consistently deficient in colonization compared to the wild-type parent (Fig. 1).

Pic contributes to colonization. In addition to testing mutants in adherence-related factors, we also addressed the potential role of the Pic mucinase in intestinal colonization of the streptomycin-treated mouse. For these initial studies, we utilized a mutant in which the *aph3* gene was inserted into *pic*. As




FIG. 1. Coinfection of streptomycin-treated mice with *E. coli* strain 042 and the dispersin mutant 042 *aap*. Mice were infected simultaneously with 2 × 10³ CFU of each strain. The bacteria were individually quantitated in fresh fecal pellets on days 1, 3, and 4. Graph represents a typical experiment with six mice in each group; bars represent the mean ratio of wild type to mutant.

with the adherence factors, strain 042 *pic::aph3* showed no defect in colonization of the streptomycin-treated mouse when tested independently.

In competition experiments, however, strain 042 *pic::aph3* was outcompeted by the wild type (Fig. 2a). Colonization of the wild-type parent strain reached ~1 × 10⁸ CFU/g feces within the first 2 days after inoculation and was generally maintained for the duration of the experiment. With the *pic* mutant, however, most of the mice colonized initially to a level of ~1 × 10⁷ to 1 × 10⁸ CFU/g feces over the first several days. However, colonization was not maintained thereafter, declining around day 7 and reaching a level of ~1 × 10⁴ to 1 × 10⁵ CFU/g after day 10. By the last 5 days of the experiment, there existed a 2- to 3-log₁₀ difference in colonization between strains 042 and 042 *pic::aph3*.

Since Pic is encoded in overlapping configuration with genes encoding the ShET1 enterotoxin, the defect of our mutant could have been due to disruption of ShET1 and/or Pic production. Attempts to complement the mutant in *trans* were unsuccessful, as the complemented strain did not grow as well as the mutant in vitro. We therefore constructed a *pic* mutant that would disrupt protease function but allow production of a noncatalytic Pic protein and an unmodified ShET1; the construction employed the allelic exchange of a single nucleotide to replace the Pic catalytic serine with alanine, retaining the native amino acid sequence on the opposite strand. This mutant was designated 042PicS258A.

In competition experiments with the wild-type strain, 042PicS258A was also impaired in colonization. The parent colonized at a level of 1 × 10⁸ to 1 × 10⁹ CFU/g feces by 40 h postinfection; this was maintained for 15 days on streptomycin (Fig. 2b). Strain 042PicS258A, however, was not able to maintain a high level of colonization. While colonization in some mice was as high as 1 × 10⁷ CFU/g feces for the first few days after inoculation, bacterial counts of the mutant gradually declined toward the lower limit of detection (~1 × 10³ CFU/g). For several mice, detectable colonization with the mutant was never established. At all time points beyond day 2, a significant




FIG. 2. Coinfection of streptomycin-treated mice with *E. coli* strain 042 and *pic* mutants. (a) Eight female BALB/c mice were infected simultaneously with 1×10^3 CFU of EAEC strain 042 (■) or strain 042 *pic::aph3* (○). Data points are \log_{10} CFU/g of fresh fecal sample collected from each mouse on days 1, 2, and 3 and approximately every other day for 15 days. The line shows the median \log_{10} CFU/g feces. A *P* value of ≤ 0.0156 was recorded for the difference between strains 042 and 042 *pic::aph3* on days 2 to 15 (except day 7) by the Wilcoxon matched-pairs signed-ranks test. (b) Nine female BALB/c mice were infected simultaneously with 1×10^3 CFU of EAEC strain 042 (■) and strain 042PIC258A (○). A *P* value of ≤ 0.0039 was recorded for the difference between strains 042 and 042PicS258A in the matched-pairs signed-ranks test.

difference (3 to 5 \log_{10}) in fecal colonization was observed between strains 042 and 042PicS258A. Thus, two independently constructed mutations in *pic* demonstrated significant and consistent defects in colonization of the mouse GI tract compared with their parent strains.

Sites of colonization by strains 042 and 042PicS258A. We sought to characterize further the mechanism of Pic's contri-

bution to colonization. We performed competition experiments in the streptomycin-treated mouse model, quantitated the inoculated strains in the intestinal lumen, within the colonic mucous layer, and associated with the tissue underlying the mucous layer.

Five mice were infected simultaneously with 1×10^3 CFU of strains 042 and 042PicS258A and sacrificed at 24 h and at 3 days postinfection. These time points were chosen to evaluate the distribution of strains very early in colonization and when the mutant was found in highest numbers in the feces (day 3). At 24 h postinoculation, we found higher numbers of strain 042 than 042PicS258A in the lumina of both the cecum and colon; few cells of either bacterium were found in the ileum. At this early time point, no strain 042PicS258A cells and comparatively low numbers of strain 042 ($\sim 1 \times 10^4$ in two mice) were detected adherent to tissues of the cecum and colon. Whereas strain 042 was more adherent at the 24-h time point, the low level of colonization limited our ability to draw statistically significant inferences.

By 3 days postinfection, EAEC bacteria were present in the ileum, cecum, and colon, but as on day 1, colonization of both strains was higher in the cecum and colon than in the ileum (Table 3). For the cecum and colon, the median CFU/g for strain 042 was approximately 3 \log_{10} greater than the *pic* mutant. This ratio of wild-type to mutant bacteria was consistently observed in the tissues and luminal contents of the cecum and colon.

To further address the potential roles of penetration and adherence, the mucous layer was scraped from a section of colon in each of the five mice, and the wild type and *pic* mutant were enumerated in the mucus and underlying colonic tissue. At 24 h, no strain 042PicS258A cells were detected and only rarely were strain 042 cells detected (in one mouse) adherent to tissues and in the mucous layer. In contrast, on day 3, there was an approximately 2- \log_{10} difference between the median CFU/g of the two strains in both the scraped mucus and underlying colon tissue (Table 3).

Thus, the higher proportion of the wild type versus the mutant was consistently observed in the lumen, mucus layer, and underlying tissue. That difference was present in the lumen by 24 h postinfection and in the lumen, mucous layer, and underlying tissue by 3 days postinfection.

Adherence to mouse colonic tissue by strain 042 and mutants. We next evaluated the relative abilities of the wild type

TABLE 3. Competitive colonization on day 3 postinfection^a

Location of colonization	Bacterial counts of indicated strain in luminal contents (\log_{10} CFU/g)				<i>P</i> value ^b	Bacterial counts of indicated strain in homogenized tissue (\log_{10} CFU/g)				<i>P</i> value ^b
	042		042PicS258A			042		042PicS258A		
	Mean	Median	Mean	Median		Mean	Median	Mean	Median	
Ileum	4.5 ± 2.1	3.0	≤3.0 ± 0.0	≤3.0	1.0	3.7 ± 0.9	3.2	≤3.0 ± 0.0	≤3.0	1.0
Cecum	8.6 ± 0.5	8.5	5.5 ± 0.7	5.59	0.004	6.1 ± 1.1	5.7	3.1 ± 0.2	3.1	0.004
Colon with mucus layer	7.9 ± 1.1	8.1	4.7 ± 0.7	4.8	0.005	6.2 ± 0.9	6.3	3.4 ± 0.5	≤3.0	0.001
Colonic mucus layer	5.5 ± 0.9	5.4	≤3.0 ± 0.0	≤3.0	0.01	5.5 ± 0.9	5.5	3.1 ± 0.1	≤3.0	0.003

^a Five mice were given 1×10^3 CFU of strains 042 and 042PicS258A simultaneously. Numbers in the table are the means ± 1 standard deviation and median \log_{10} CFU/g tissue or per milliliter of contents at 3 days postinfection. Limit of detection was approximately 1×10^3 CFU/g. If no organisms were detected, mean and median are recorded as $\leq 3.0 \log_{10}$ CFU/g.

^b *P* values for the difference between the mean colonization of strains 042 and 042PicS258A for each site were determined by using the paired *t* test of log-transformed data. If none was detected, the *P* value is based on 3 \log_{10} CFU/g.




FIG. 3. Growth of strain 042 (■) and strain 042PicS258A (○) in a mixed culture in a continuous-flow anaerobic culture system with human fecal bacteria (a) or without addition of a human fecal sample (b). Growth is expressed as means \pm 1 standard deviation \log_{10} CFU/ml of two samples removed from the system at the indicated time points.

and mutant to adhere to fresh colonic tissue excised from a streptomycin-treated mouse in an ex vivo format, using the previously described Snapwell system (10), in which tissue is mounted between two plastic disks and bathed in cell culture medium with separation of mucosal and serosal surfaces into distinct compartments. EAEC strains were more adherent to the mouse colonic mucosa than commensal *E. coli* HS; however, there was no difference in the ability of strain 042, 042PicS258A, or 042 *pic::aph3* to adhere to the tissue when cultured individually (data not shown). Similarly, coculture of strain 042 with either mutant strain did not show any differences in relative adherence.

In vitro growth characteristics of *pic* mutants. Either individually or in coculture, the *pic* mutants grew at rates similar to that of their wild-type parent in L broth cultures. Both mutants retained the ability to form a biofilm on polystyrene (42) and displayed motilities similar to that of the parent strain (data not shown).

We addressed whether the colonization deficiency of the *pic* mutants could be due to differences in anaerobic growth. To test this hypothesis, we employed the continuous-flow anaerobic culture system established in our laboratory to simulate the microenvironment of the human colon (37). The growth medium for these experiments has been established for EAEC strain 042 (37). An advantage of this system is that the growth characteristics of a test strain can be assessed in the presence or absence of other fecal bacteria.

The culture system was equilibrated with a human fecal sample and then inoculated with a mixed culture of 042 and 042PicS258A to a concentration of $\sim 1 \times 10^7$ CFU/ml of each




FIG. 4. Relative growth in cecal mucus and cecal contents. Tubes containing cecal mucus (filled symbols) or cecal contents (open symbols) were inoculated simultaneously with a mixture of 10^4 CFU of strain 042 (squares; solid lines) and 10^4 CFU of strain 042PicS258A (circles; dashed lines) and incubated at 37°C with aeration. At the times indicated, tubes were sampled to determine viable counts. Bars representing the standard error of the mean \log_{10} CFU/ml for duplicate experiments are presented for each time point.

strain. Growth of each strain was monitored for 5 days. Colony counts gradually declined for 48 h but then stabilized at $\sim 1 \times 10^5$ to 1×10^6 CFU/ml. No significant difference in growth between the wild type and the *pic* mutant was observed (Fig. 3a). We then repeated these experiments but without the addition of the fecal inoculum. Without competition from other bacteria, EAEC increased in numbers for the first 12 h and then declined to a steady-state level of $\sim 6.5 \log_{10}$ CFU/ml (Fig. 3b). Again, no significant difference between the wild type and mutant was seen. The competitive advantage of strain 042 in vivo was therefore not reproduced with the intestinal simulator, suggesting that the advantage conferred by the Pic protein was due to neither enhanced fitness for anaerobic growth nor improved competition with typical human commensal flora.

Growth in cecal mucus and luminal contents. As a mucinase, Pic could hypothetically enhance fitness via improved use of nutrients derived from some luminal component, perhaps mucin itself. We therefore evaluated growth in mucus and cecal luminal contents harvested from the intestines of mice. Luminal contents and mucus were extracted separately and inoculated with 1×10^4 CFU of strains 042 and 042PicS258A and then cultured aerobically and sampled over time.

As shown in Fig. 4, the strains grew similarly for the first 6 h of cocultivation, with similar generation times of 33 to 40 min. However, at the 8-h time point and subsequently, growth of strain 042PicS258A slowed, with a generation time increasing to 53 min at 6 to 8 h; in contrast, strain 042 continued to grow in mucus for the duration of the experiment, and the 6- to 8-h generation time was approximately 32 min. Growth in cecal contents for both strains was slow, yet numbers increased for strain 042 over the 24 h of the experiment and declined slightly for strain 042PicS258A. This experiment was repeated using longer incubation times; the difference in growth between the




FIG. 5. Pic enhances growth of strain 042 in the presence of mucin. Thirteen-hour growth curves of wild-type strain 042 and strain 042PicS258A (042S) are shown in M9 minimal medium with 0.05% glucose, with and without the addition of mucin after 5 h of incubation (arrow). Results are typical of repeated experiments; measurements are performed in triplicate with an error of <0.003 U for all points.

two strains in mucus was reproducible and remained significant up to 48 h (data not shown).

The fact that strains 042 and 042PicS258A grew similarly in mucus for several hours, after which time strain 042 exhibited superior growth, suggested that Pic was providing some metabolic advantage to the bacterium, presumably after the exhaustion of a more readily available nutrient. An alternative hypothesis was that mucin was inhibiting the growth of the bacterium, with this inhibition being relieved by Pic. To test these alternative hypotheses, we characterized growth curves of strain 042 versus strain 042PicS258A in M9 minimal medium containing 0.05% glucose to which bovine submaxillary mucin was added during logarithmic phase (after 5 h of growth). As shown in Fig. 5, strains 042 and 042PicS258A entered stationary growth phase at similar times. However, the wild type then resumed slow growth for several additional hours, whereas the Pic mutant remained at a uniform OD₆₀₀.

DISCUSSION

Our studies suggest that the streptomycin-treated mouse model has some advantages and some limitations for the study of EAEC colonization factors. The AAF/II fimbriae of strain 042 are essential for adherence to the human intestine *ex vivo* but were not shown to confer a colonization advantage in the mouse. This is in spite of our observation that AAF/II fimbriae enhance adherence to the mouse intestinal mucosa *in vitro*.

Why adherence does not translate into increased colonization is not apparent. Interestingly, however, the dispersin protein required for normal morphology of the AAF adhesins and which modulates EAEC aggregation was found to be required for efficient colonization. We have demonstrated previously that EAEC bacteria lacking dispersin are highly aggregated and move more slowly than bacteria of strain 042 through a viscous column of purified mucin (40). The effect of the dispersin mutant in the mouse was apparently dependent on expression of the AAF adhesin, as the *aggR* mutant, unable to make either dispersin or AAF, no longer exhibited any colonization disadvantage. These experiments do not exclude a role for an as-yet-unidentified AggR-dependent factor. Further characterization of the contribution of dispersin will be published elsewhere.

Our studies did not reveal a role for the newly discovered chromosomally encoded aggregin, Air, which is under the control of the HilA-like regulator EilA (41). Like absence of dispersin, the presence of Air promotes aggregation of bacteria. It is interesting, therefore, that our data suggest no influence of Air on colonization of the mouse. It is possible that the natural role of Air could be in EAEC adherence outside of the host, or perhaps the role is complex and relevant at later stages in the colonization process.

Given the occurrence of the Pic mucinase in EAEC, *Shigella* spp., and UPEC strains, we were particularly interested in its possible contribution to colonization. A number of studies have demonstrated two stages of colonization for *E. coli* in the streptomycin-treated mouse model (26, 46). When fed alone to mice, low numbers of bacteria (1×10^5) will increase to between 1×10^8 and 1×10^9 CFU/g feces within 1 to 3 days postinfection; this is postulated to be due to limited competition for nutrients from other aerobic species. After this initiation phase, however, counts of *E. coli* will diminish to approximately 1×10^7 to 1×10^8 CFU/g feces, where they will remain indefinitely; this second stage has been termed the maintenance stage (6). The maintenance stage is thought to represent stable establishment of a metabolic niche within the intestine, in which the bacteria metabolize some carbon sources better than the incumbent microflora. When fed individually, both strain 042 and two different *pic* mutants were able to colonize to high numbers and remained stable for the 12 days of the experiment, exhibiting normal initiation and maintenance phases. However, when fed to mice simultaneously, the wild type maintained its level of colonization at 1×10^7 to 1×10^8 CFU/g feces, whereas the *pic* mutants initiated infection in some mice but failed to maintain it, gradually declining to between 1×10^3 and 1×10^5 CFU/g feces. This reveals the relative superiority of the wild type for maintaining colonization of the GI niche and suggests a metabolic advantage of the wild type.

We had initially speculated that the mechanism of Pic's effect would involve penetration of the mucus layer. However, the superiority of the parent over its *pic* mutant was apparent at all sites and environments of the GI tract, including at the lumen and the mucus layer, as well as at the level of the epithelial surface. Two bacterial metalloproteases have been reported to have mucinase activity and also to contribute to bacterial adherence. StcE, in enterohemorrhagic *E. coli* O157:H7, promotes intimate adherence to HEP-2 cells (14), and Hap

of *Vibrio cholerae* acts as a detachase, freeing adherent bacteria (2). However, we did not find evidence to suggest that the role of Pic included adherence. Nor did our data suggest increased fitness in aerobic or anaerobic environments, even in the presence of fecal bacteria.

In aggregate, our data are most consistent with a metabolic role for Pic, dependent on its mucinase activity and presumably by allowing the use of mucus as a growth substrate. Using the streptomycin-treated mouse model, *E. coli* has been shown to utilize gluconate in mucus as a major carbon source (45). Notably, we found that EAEC strain 042 and its *pic* mutant grew equally well in cecal mucus in vitro for approximately the first 6 h, indicating that both strains utilize gluconate or another nutrient equally during this time period. However, after 6 to 8 h, growth of the mutant slowed considerably, whereas strain 042 continued rapid growth for at least 48 additional hours. This model, therefore, recapitulated the in vivo effect. In standard growth media, including M9 minimal medium containing glucose, strain 042 and an isogenic mutant lacking only the Pic catalytic serine grew equally well. However, when mucin was added to the medium, strain 042 demonstrated more robust growth, beginning after the initiation of stationary phase. The similar growth rates early in the experiment suggest that glucose may be a preferred substrate for both the wild type and the *pic* mutant but that the use of mucus as a substrate occurs when other preferred substrates are limiting; limitation may prevail either because preferred substrates are not present at that intestinal site or because they are more efficiently utilized by competing microflora.

Our data therefore strongly support the hypothesis that the contribution of Pic to intestinal colonization is nutritional. The fact that both the wild type and the *pic* mutant grow well initially in mouse mucus preparations prior to the deviation of the growth curves supports this interpretation of the data. Whether the postulated advantage of Pic occurs via the release of glycans from intestinal mucus and/or from degradation of the mucin protein backbone cannot be determined from our data, and it is the subject of ongoing studies in our laboratories. Moreover, the presence of Pic in *Shigella* spp. and UPEC strains and the presence of mucinolytic Pic homologs in other pathogens suggest that our observations may have implications for pathogens other than EAEC.

ACKNOWLEDGMENTS

We gratefully acknowledge Alessio Fasano and Klara Margaretten for assistance with the adherence experiments, Araceli Santiago for assistance with the mouse infection technique, and Alfredo Torres for helpful suggestions regarding the allelic exchange protocol.

This work was supported by U.S. PHS grants AI33096, AI43615, and AI03615 to J.P.N. and AI48945 to P.S.C.

REFERENCES

- Adachi, J. A., Z. D. Jiang, J. J. Mathewson, M. P. Venkar, S. Thompson, F. Martinez-Sandoval, R. Steffen, C. D. Ericsson, and H. L. DuPont. 2001. Enteroregative *Escherichia coli* as a major etiologic agent in traveler's diarrhea in 3 regions of the world. *Clin. Infect. Dis.* **32**:1706–1709.
- Bénitez, J. A., R. G. Spelbrink, A. Silva, T. E. Phillips, C. M. Stanley, M. Boesman-Finkelstein, and R. A. Finkelstein. 1997. Adherence of *Vibrio cholerae* to cultured differentiated human intestinal cells: an in vitro colonization model. *Infect. Immun.* **65**:3474–3477.
- Benjelloun-Touimi, Z., P. J. Sansonetti, and C. Parsot. 1995. SepA, the major extracellular protein of *Shigella flexneri*: autonomous secretion and involvement in tissue invasion. *Mol. Microbiol.* **17**:123–135.
- Bhan, M. K., V. Khoshoo, H. Sommerfelt, P. Raj, S. Sazawal, and R. Srivastava. 1989. Enteroregative *Escherichia coli* and *Salmonella* associated with nondysenteric persistent diarrhea. *Pediatr. Infect. Dis. J.* **8**:499–502.
- Bhan, M. K., P. Raj, M. M. Levine, J. B. Kaper, N. Bhandari, R. Srivastava, R. Kumar, and S. Sazawal. 1989. Enteroregative *Escherichia coli* associated with persistent diarrhea in a cohort of rural children in India. *J. Infect. Dis.* **159**:1061–1064.
- Chang, D. E., D. J. Smalley, D. L. Tucker, M. P. Leatham, W. E. Norris, S. J. Stevenson, A. B. Anderson, J. E. Grissom, D. C. Laux, P. S. Cohen, and T. Conway. 2004. Carbon nutrition of *Escherichia coli* in the mouse intestine. *Proc. Natl. Acad. Sci. USA* **101**:7427–7432.
- Czczulin, J. R., S. Balepur, S. Hicks, A. Phillips, R. Hall, M. H. Kothary, F. Navarro-Garcia, and J. P. Nataro. 1997. Aggregative adherence fimbria II, a second fimbrial antigen mediating aggregative adherence in enteroregative *Escherichia coli*. *Infect. Immun.* **65**:4135–4145.
- Donnenberg, M. S., and J. B. Kaper. 1991. Construction of an *eae* deletion mutant of enteropathogenic *Escherichia coli* by using a positive-selection suicide vector. *Infect. Immun.* **59**:4310–4317.
- Dutta, P. R., R. Cappello, F. Navarro-Garcia, and J. P. Nataro. 2002. Functional comparison of serine protease autotransporters of *Enterobacteriaceae*. *Infect. Immun.* **70**:7105–7113.
- El Asmar, R., P. Panigrahi, P. Bamford, I. Berti, T. Not, G. V. Coppa, C. Catassi, and A. Fasano. 2002. Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. *Gastroenterology* **123**:1607–1615.
- Fasano, A., F. R. Noriega, F. M. Liao, W. Wang, and M. M. Levine. 1997. Effect of *Shigella* enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo. *Gut* **40**:505–511.
- Fasano, A., F. R. Noriega, D. R. Maneval, Jr., S. Chanasongram, R. Russell, S. Guandalini, and M. M. Levine. 1995. *Shigella* enterotoxin 1: an enterotoxin of *Shigella flexneri* 2a active in rabbit small intestine in vivo and in vitro. *J. Clin. Investig.* **95**:2853–2861.
- Germani, Y., P. Minssart, M. Vohito, S. Yassibanda, P. Glaziou, D. Hocquet, P. Berthelemy, and J. Morvan. 1998. Etiologies of acute, persistent, and dysenteric diarrheas in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus. *Am. J. Trop. Med. Hyg.* **59**:1008–1014.
- Grys, T. E., M. B. Siegel, W. W. Lathem, and R. A. Welch. 2005. The StcE protease contributes to intimate adherence of enterohemorrhagic *Escherichia coli* O157:H7 to host cells. *Infect. Immun.* **73**:1295–1303.
- Guyer, D. M., J. S. Kao, and H. L. Mobley. 1998. Genomic analysis of a pathogenicity island in uropathogenic *Escherichia coli* CFT073: distribution of homologous sequences among isolates from patients with pyelonephritis, cystitis, and catheter-associated bacteriuria and from fecal samples. *Infect. Immun.* **66**:4411–4417.
- Heimer, S. R., D. A. Rasko, C. V. Lockett, D. E. Johnson, and H. L. Mobley. 2004. Autotransporter genes *pic* and *tsh* are associated with *Escherichia coli* strains that cause acute pyelonephritis and are expressed during urinary tract infection. *Infect. Immun.* **72**:593–597.
- Henderson, I. R., J. Czczulin, C. Eslava, F. Noriega, and J. P. Nataro. 1999. Characterization of Pic, a secreted protease of *Shigella flexneri* and enteroregative *Escherichia coli*. *Infect. Immun.* **67**:5587–5596.
- Henderson, I. R., and J. P. Nataro. 2001. Virulence functions of autotransporter proteins. *Infect. Immun.* **69**:1231–1243.
- Huang, D. B., J. P. Nataro, H. L. DuPont, P. P. Kamat, A. D. Mhatre, P. C. Okhuysen, and T. Chiang. 2006. Enteroregative *Escherichia coli* is a cause of acute diarrheal illness: a meta-analysis. *Clin. Infect. Dis.* **43**:556–563.
- Itoh, Y., I. Nagano, M. Kumishima, and T. Ezaki. 1997. Laboratory investigation of enteroregative *Escherichia coli* O untypeable:H10 associated with a massive outbreak of gastrointestinal illness. *J. Clin. Microbiol.* **35**:2546–2550.
- Knutton, S., R. K. Shaw, M. K. Bhan, H. R. Smith, M. M. McConnell, T. Cheasty, P. H. Williams, and T. J. Baldwin. 1992. Ability of enteroregative *Escherichia coli* strains to adhere in vitro to human intestinal mucosa. *Infect. Immun.* **60**:2083–2091.
- Kobayashi, R. K., L. C. Gaziri, E. J. Venancio, and M. C. Vidotto. 2007. Detection of Tsh protein mucinolytic activity by SDS-PAGE. *J. Microbiol. Methods* **68**:654–655.
- Levine, M. M., C. Ferreccio, V. Prado, M. Cayazzo, P. Abrego, J. Martinez, L. Maggi, M. M. Baldini, W. Martin, D. Maneval, B. Kay, L. Guers, H. Lior, S. S. Wasserman, and J. P. Nataro. 1993. Epidemiologic studies of *Escherichia coli* diarrheal infections in a low socioeconomic level peri-urban community in Santiago, Chile. *Am. J. Epidemiol.* **138**:849–869.
- Leyton, D. L., J. Sloan, R. E. Hill, S. Doughty, and E. L. Hartland. 2003. Transfer region of pO113 from enterohemorrhagic *Escherichia coli*: similarity with R64 and identification of a novel plasmid-encoded autotransporter, EpeA. *Infect. Immun.* **71**:6307–6319.
- McCormick, B. A., P. Klemm, K. A. Krogfelt, R. L. Burghoff, L. Pallesen, D. C. Laux, and P. S. Cohen. 1993. *Escherichia coli* F-18 phase locked 'on' for expression of type 1 fimbriae is a poor colonizer of the streptomycin-treated mouse large intestine. *Microb. Pathog.* **14**:33–43.
- Miranda, R. L., T. Conway, M. P. Leatham, D. E. Chang, W. E. Norris, J. H.

- Allen, S. J., Stevenson, D. C. Laux, and P. S. Cohen. 2004. Glycolytic and gluconeogenic growth of *Escherichia coli* O157:H7 (EDL933) and *E. coli* K-12 (MG1655) in the mouse intestine. *Infect. Immun.* **72**:1666–1676.
27. Møller, A. K., M. P. Leatham, T. Conway, P. J. Nuijten, L. A. de Haan, K. A. Krogfelt, and P. S. Cohen. 2003. An *Escherichia coli* MG1655 lipopolysaccharide deep-rough core mutant grows and survives in mouse cecal mucus but fails to colonize the mouse large intestine. *Infect. Immun.* **71**:2142–2152.
28. Nataro, J. P., Y. Deng, D. R. Maneval, A. L. German, W. C. Martin, and M. M. Levine. 1992. Aggregative adherence fimbriae I of enteroaggregative *Escherichia coli* mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. *Infect. Immun.* **60**:2297–2304.
29. Nataro, J. P., D. Yikang, S. Cookson, A. Cravioto, S. J. Savarino, L. D. Guers, M. M. Levine, and C. O. Tacket. 1995. Heterogeneity of enteroaggregative *Escherichia coli* virulence demonstrated in volunteers. *J. Infect. Dis.* **171**:465–468.
30. Nataro, J. P., D. Yikang, D. Yingkang, and K. Walker. 1994. AggR, a transcriptional activator of aggregative adherence fimbria I expression in enteroaggregative *Escherichia coli*. *J. Bacteriol.* **176**:4691–4699.
31. Navarro-García, F., A. Canizalez-Roman, J. Luna, C. Sears, and J. P. Nataro. 2001. Plasmid-encoded toxin of enteroaggregative *Escherichia coli* is internalized by epithelial cells. *Infect. Immun.* **69**:1053–1060.
32. Nevala, J. J., D. C. Laux, and P. S. Cohen. 1987. In vivo colonization of the mouse large intestine and in vitro penetration of intestinal mucus by an avirulent smooth strain of *Salmonella typhimurium* and its lipopolysaccharide-deficient mutant. *Infect. Immun.* **55**:2884–2890.
33. Otto, B. R., S. J. van Dooren, J. H. Nuijens, J. Luirink, and B. Oudega. 1998. Characterization of a hemoglobin protease secreted by the pathogenic *Escherichia coli* strain EB1. *J. Exp. Med.* **188**:1091–1103.
34. Parham, N. J., U. Srinivasan, M. Desvaux, B. Foxman, C. F. Marrs, and I. R. Henderson. 2004. PicU, a second serine protease autotransporter of uropathogenic *Escherichia coli*. *FEMS Microbiol. Lett.* **230**:73–83.
35. Piva, I. C., A. L. Pereira, L. R. Ferraz, R. S. Silva, A. C. Vieira, J. E. Blanco, M. Blanco, J. Blanco, and L. G. Giugliano. 2003. Virulence markers of enteroaggregative *Escherichia coli* isolated from children and adults with diarrhea in Brasilia, Brazil. *J. Clin. Microbiol.* **41**:1827–1832.
36. Rajakumar, K., C. Sasakawa, and B. Adler. 1997. Use of a novel approach, termed island probing, identifies the *Shigella flexneri* she pathogenicity island which encodes a homolog of the immunoglobulin A protease-like family of proteins. *Infect. Immun.* **65**:4606–4614.
37. Ruiz-Perez, F., J. Sheikh, S. Davis, E. C. Boedeker, and J. P. Nataro. 2004. Use of a continuous-flow anaerobic culture to characterize enteric virulence gene expression. *Infect. Immun.* **72**:3793–3802.
38. Sarantuya, J., J. Nishi, N. Wakimoto, S. Erdene, J. P. Nataro, J. Sheikh, M. Iwashita, K. Manago, K. Tokuda, M. Yoshinaga, K. Miyata, and Y. Kawano. 2004. Typical enteroaggregative *Escherichia coli* is the most prevalent pathotype among *E. coli* strains causing diarrhea in Mongolian children. *J. Clin. Microbiol.* **42**:133–139.
39. Savarino, S., A. Fasano, D. Robertson, and M. Levine. 1991. Enteroaggregative *Escherichia coli* elaborate a heat-stable enterotoxin demonstrable in an in vitro intestinal model. *J. Clin. Invest.* **87**:1450–1455.
40. Sheikh, J., J. R. Czeuczulin, S. Harrington, S. Hicks, I. R. Henderson, B. C. Le, P. Gounon, A. Phillips, and J. P. Nataro. 2002. A novel dispersin protein in enteroaggregative *Escherichia coli*. *J. Clin. Invest.* **110**:1329–1337.
41. Sheikh, J., E. G. Dudley, B. Sui, B. Tamboura, A. Suleman, and J. P. Nataro. 2006. EilA, a HilA-like regulator in enteroaggregative *Escherichia coli*. *Mol. Microbiol.* **61**:338–350.
42. Sheikh, J., S. Hicks, M. Dall'Agnol, A. D. Phillips, and J. P. Nataro. 2001. Roles for Fis and YafK in biofilm formation by enteroaggregative *Escherichia coli*. *Mol. Microbiol.* **41**:983–997.
43. Stathopoulos, C., D. L. Provenge, and R. Curtiss III. 1999. Characterization of the avian pathogenic *Escherichia coli* hemagglutinin Tsh, a member of the immunoglobulin A protease-type family of autotransporters. *Infect. Immun.* **67**:772–781.
44. Stecher, B., G. Paesold, M. Barthel, M. Kremer, J. Jantsch, T. Stallmach, M. Heikenwalder, and W. D. Hardt. 2006. Chronic *Salmonella enterica* serovar Typhimurium-induced colitis and cholangitis in streptomycin-pretreated *Nramp1*^{+/+} mice. *Infect. Immun.* **74**:5047–5057.
45. Sweeney, N. J., D. C. Laux, and P. S. Cohen. 1996. *Escherichia coli* F-18 and *E. coli* K-12 *eda* mutants do not colonize the streptomycin-treated mouse large intestine. *Infect. Immun.* **64**:3504–3511.
46. Wadolkowski, E. A., D. C. Laux, and P. S. Cohen. 1988. Colonization of the streptomycin-treated mouse large intestine by a human fecal *Escherichia coli* strain: role of growth in mucus. *Infect. Immun.* **56**:1030–1035.

Editor: B. A. McCormick